Yatin Suneja

Stock Analyst at Guggenheim

(0.76)
# 2101
Out of 5,318 analysts
141
Total ratings
40.24%
Success rate
-6.04%
Average return
45 Stocks
Name Action Price Target Current % Upside Ratings Updated
PHAT Phathom Pharmaceutic...
Reiterates: Buy
n/a
n/a n/a 3 Apr 2, 2025
CABA Cabaletta Bio
Reiterates: Buy
23 23
1.29 1682.95% 3 Apr 1, 2025
ZURA Zura Bio
Reiterates: Buy
15 15
1.42 956.34% 2 Mar 26, 2025
IFRX InflaRx
Maintains: Strong Buy
7 10
1.31 663.36% 5 Mar 26, 2025
LRMR Larimar Therapeutics
Reiterates: Buy
26 26
2.35 1006.38% 4 Mar 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
7 7
0.61 1047.54% 1 Mar 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 8 Mar 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
84 84
21.27 294.92% 1 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
45 45
9.7 363.92% 3 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
775 1100
598.46 83.81% 9 Mar 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Mar 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
165 163
105.17 54.99% 4 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 3 Jan 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
45 45
n/a n/a 3 Jan 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
20 20
14.79 35.23% 6 Jan 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
90 36
20.24 77.87% 11 Dec 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Dec 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 2 Dec 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
50 65
14.81 338.89% 1 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
155 170
36.03 371.83% 2 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1180 1300
595.26 118.39% 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
32
4.29 645.92% 1 Jul 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 May 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
6.92 622.54% 1 Apr 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
72 90
19.53 360.83% 4 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
110 125
105.51 18.47% 8 Feb 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
16 32
n/a n/a 3 Jan 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Dec 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
17 16
10.97 45.85% 2 Nov 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
70 77
39.44 95.23% 3 Nov 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Sep 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Jul 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
49
38.18 28.34% 2 Jun 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
52 55
6.54 740.98% 2 May 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
270 350
119.39 193.16% 3 May 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
225 200
n/a n/a 3 Apr 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 5 Jan 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
98 117
n/a n/a 1 Dec 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
75
n/a n/a 1 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Oct 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
24
13.55 77.12% 1 May 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Apr 26, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
29 34
65.19 -47.84% 2 Jan 14, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
n/a
n/a n/a 1 Feb 22, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
60 80
n/a n/a 2 Jun 11, 2018